{"id":3883,"date":"2020-04-30T10:39:03","date_gmt":"2020-04-30T08:39:03","guid":{"rendered":"https:\/\/centroandaluzalfa1.org\/?p=3883"},"modified":"2020-05-03T18:06:35","modified_gmt":"2020-05-03T16:06:35","slug":"covid-19-respiratory-patients","status":"publish","type":"post","link":"https:\/\/centroandaluzalfa1.org\/en\/covid-19-respiratory-patients\/","title":{"rendered":"COVID 19 RESPIRATORY PATIENTS"},"content":{"rendered":"\n

The Spanish Society of Pneumology and Thoracic Surgery (SEPAR) answers questions from patients about COVID-19, in a series of short videos promoted by the Spanish Federation of Associations of allergic and Respiratory Diseases (FENAER), in collaboration with SEPAR Patients and the specialized channel Medicine TV.<\/strong><\/p>\n\n\n\n

Within its objective of providing truthful information in relation to COVID-19, FENAER has promoted the production of a series of videos in which specialists in reference pulmonology, answer questions posed by patients with respiratory pathologies, opening a direct route of doctor-patient communication in now very difficult circumstances, making it more difficult for patients to access their doctors to resolve their concerns.<\/p>\n\n\n\n

Dr. Francisco Casas, member of the Committee of the Spanish Registry of patients with Alpha-1 antitrypsin deficiency (REDAAT) and coordinator of the Andalusian Alpha-1 Center of Granada of the HU Clinico San Cecilio, answers the following questions raised by the Association Alfa-1 from Spain in relation to the interruption to many patients of the replacement treatment of Alfa-1 due to the high risk of infection in hospitals.<\/p>\n\n\n\n

1) Are they more exposed to developing complications without the protection of the treatment?<\/p>\n\n\n\n

2) Should they request its administration in case of developing pneumonia?<\/p>\n\n\n\n

3) Is it known whether lack of protection can accelerate the loss of lung tissue?<\/p>\n\n\n\n

\n